{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:14:56Z","timestamp":1791220496485,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T00:00:00Z","timestamp":1385424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T00:00:00Z","timestamp":1385424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/nrurol.2013.274","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T09:12:18Z","timestamp":1385457138000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["CYP17 inhibitors\u2014abiraterone, C17,20-lyase inhibitors and multi-targeting agents"],"prefix":"10.1038","volume":"11","author":[{"given":"Lina","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,26]]},"reference":[{"key":"BFnrurol2013274_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10\u201329 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrurol2013274_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ejca.2009.09.008","volume":"46","author":"PJ van Leeuwen","year":"2010","unstructured":"van Leeuwen, P. J.  et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur. J. Cancer 46, 377\u2013383 (2010).","journal-title":"Eur. J. Cancer"},{"key":"BFnrurol2013274_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel, R.  et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220\u2013241 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrurol2013274_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/jnci\/djp278","volume":"101","author":"HG Welch","year":"2009","unstructured":"Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986\u20132005. J. Natl Cancer Inst. 101, 1325\u20131329 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol2013274_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa012794","volume":"347","author":"L Holmberg","year":"2002","unstructured":"Holmberg, L.  et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 347, 781\u2013789 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2013274_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1470-2045(04)01384-1","volume":"5","author":"C Parker","year":"2004","unstructured":"Parker, C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 5, 101\u2013106 (2004).","journal-title":"Lancet Oncol."},{"key":"BFnrurol2013274_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.7326\/0003-4819-155-3-201108020-00347","volume":"155","author":"RR Bannuru","year":"2011","unstructured":"Bannuru, R. R.  et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann. Intern. Med. 155, 171\u2013178 (2011).","journal-title":"Ann. Intern. Med."},{"key":"BFnrurol2013274_CR8","first-page":"1630","volume-title":"Current Medical Diagnosis and Treatment 2013","author":"MV Meng","year":"2013","unstructured":"Meng, M. V. in Current Medical Diagnosis and Treatment 2013 (eds Papadakis, M. A., McPhee, S. J. & Rabow, M. W.) 1630\u20131638 (The McGraw-Hill Medical, 2013)."},{"issue":"Suppl. 3","key":"BFnrurol2013274_CR9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/1097-0142(19930201)71:3+<1039::AID-CNCR2820711423>3.0.CO;2-H","volume":"71","author":"J Geller","year":"1993","unstructured":"Geller, J. Basis for hormonal management of advanced prostate cancer. Cancer 71 (Suppl. 3), 1039\u20131045 (1993).","journal-title":"Cancer"},{"key":"BFnrurol2013274_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1442-2042.2008.02074.x","volume":"15","author":"T Imamoto","year":"2008","unstructured":"Imamoto, T.  et al. The role of testosterone in the pathogenesis of prostate cancer. Int. J. Urol. 15, 472\u2013480 (2008).","journal-title":"Int. J. Urol."},{"key":"BFnrurol2013274_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W.  et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2013274_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson, S.  et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587\u2013589 (2007).","journal-title":"Lancet Oncol."},{"key":"BFnrurol2013274_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi, K.  et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813\u2013822 (2011).","journal-title":"Lancet"},{"key":"BFnrurol2013274_CR14","doi-asserted-by":"publisher","first-page":"13958","DOI":"10.3390\/ijms140713958","volume":"14","author":"L Yin","year":"2013","unstructured":"Yin, L., Hu, Q. & Hartmann, R. W. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int. J. Mol. Sci. 14, 13958\u201313978 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"BFnrurol2013274_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000179774","volume":"18","author":"P Franchimont","year":"1983","unstructured":"Franchimont, P. Regulation of gonadal androgen secretion. Horm. Res. 18, 7\u201317 (1983).","journal-title":"Horm. Res."},{"key":"BFnrurol2013274_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jsbmb.2007.09.015","volume":"108","author":"WE Rainey","year":"2008","unstructured":"Rainey, W. E. & Nakamura, Y. Regulation of the adrenal androgen biosynthesis. J. Steroid. Biochem. Mol. Biol. 108, 281\u2013286 (2008).","journal-title":"J. Steroid. Biochem. Mol. Biol."},{"key":"BFnrurol2013274_CR17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1101\/gad.1564207","volume":"21","author":"EC Bolton","year":"2007","unstructured":"Bolton, E. C.  et al. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21, 2005\u20132017 (2007).","journal-title":"Genes Dev."},{"key":"BFnrurol2013274_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1677\/ERC-08-0084","volume":"15","author":"ML Zhu","year":"2008","unstructured":"Zhu, M. L. & Kyprianou, N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 15, 841\u2013849 (2008).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrurol2013274_CR19","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1093\/emboj\/19.20.5406","volume":"19","author":"A Migliaccio","year":"2000","unstructured":"Migliaccio, A.  et al. Steroid-induced androgen receptor-oestradiol receptor \u03b2-Src complex triggers prostate cancer cell proliferation. EMBO J. 19, 5406\u20135417 (2000).","journal-title":"EMBO J."},{"key":"BFnrurol2013274_CR20","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","volume":"11","author":"MA Titus","year":"2005","unstructured":"Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653\u20134657 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2013274_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5","volume":"29","author":"H Suzuki","year":"1996","unstructured":"Suzuki, H.  et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29, 153\u2013158 (1996).","journal-title":"Prostate"},{"key":"BFnrurol2013274_CR22","first-page":"149","volume":"63","author":"T Hara","year":"2003","unstructured":"Hara, T.  et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149\u2013153 (2003).","journal-title":"Cancer Res."},{"key":"BFnrurol2013274_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/76287","volume":"6","author":"XY Zhao","year":"2000","unstructured":"Zhao, X. Y.  et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703\u2013706 (2000).","journal-title":"Nat. Med."},{"key":"BFnrurol2013274_CR24","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai, C.  et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71, 6503\u20136513 (2011).","journal-title":"Cancer Res."},{"key":"BFnrurol2013274_CR25","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery, R. B.  et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447\u20134454 (2008).","journal-title":"Cancer Res."},{"key":"BFnrurol2013274_CR26","doi-asserted-by":"publisher","first-page":"13728","DOI":"10.1073\/pnas.1107898108","volume":"108","author":"KH Chang","year":"2011","unstructured":"Chang, K. H.  et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728\u201313733 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol2013274_CR27","doi-asserted-by":"publisher","first-page":"5844","DOI":"10.1158\/1078-0432.CCR-11-0644","volume":"17","author":"JL Mohler","year":"2011","unstructured":"Mohler, J. L., Titus, M. A. & Wilson, E. M. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin. Cancer Res. 17, 5844\u20135849 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2013274_CR28","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0022-5347(01)64924-3","volume":"157","author":"EJ Small","year":"1997","unstructured":"Small, E. J., Baron, A. D., Fippin, L. & Apodaca, D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 157, 1204\u20131207 (1997).","journal-title":"J. Urol."},{"key":"BFnrurol2013274_CR29","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard, G.  et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563\u20134571 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature10743","volume":"482","author":"NM DeVore","year":"2012","unstructured":"DeVore, N. M. & Scott, E. E. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482, 116\u2013120 (2012).","journal-title":"Nature"},{"key":"BFnrurol2013274_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cmdc.201000065","volume":"5","author":"Q Hu","year":"2010","unstructured":"Hu, Q., Negri, M., Olgen, S. & Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma. Chem. Med. Chem. 5, 899\u2013910 (2010).","journal-title":"Chem. Med. Chem."},{"key":"BFnrurol2013274_CR32","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1021\/jm100400a","volume":"53","author":"Q Hu","year":"2010","unstructured":"Hu, Q., Yin, L., Jagusch, C., Hille, U. E. & Hartmann, R. W. Isopropylidene substitution increases activity and selectivity of biphenyl methylene 4-pyridine type CYP17 inhibitors. J. Med. Chem. 53, 5049\u20135053 (2010).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR33","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.1016\/j.bmc.2008.07.011","volume":"16","author":"Q Hu","year":"2008","unstructured":"Hu, Q.  et al. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17\u03b1-hydroxylase-17,20-lyase (CYP17)\u2014part II: core rigidification and influence of substituents at the methylene bridge. Bioorg. Med. Chem. 16, 7715\u20137727 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"BFnrurol2013274_CR34","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.ejmech.2009.01.002","volume":"44","author":"UE Hille","year":"2009","unstructured":"Hille, U. E.  et al. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. Eur. J. Med. Chem. 44, 2765\u20132775 (2009).","journal-title":"Eur. J. Med. Chem."},{"key":"BFnrurol2013274_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ardp.200700251","volume":"341","author":"MA Pinto-Bazurco Mendieta","year":"2008","unstructured":"Pinto-Bazurco Mendieta, M. A.  et al. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling. Arch. Pharm. (Weinheim) 341, 597\u2013609 (2008).","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"BFnrurol2013274_CR36","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1016\/j.bmc.2007.10.094","volume":"16","author":"C Jagusch","year":"2008","unstructured":"Jagusch, C.  et al. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17\u03b1-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure. Bioorg. Med. Chem. 16, 1992\u20132010 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"BFnrurol2013274_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1039\/c2md20072d","volume":"3","author":"AH Abadi","year":"2012","unstructured":"Abadi, A. H., Abou-Seri, S. M., Hu, Q., Negri, M. & Hartmann, R. W. Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors. Med. Chem. Comm. 3, 663\u2013666 (2012).","journal-title":"Med. Chem. Comm."},{"key":"BFnrurol2013274_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.crci.2009.03.007","volume":"12","author":"UE Hille","year":"2009","unstructured":"Hille, U. E.  et al. Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile. C. R. Chim. 12, 1117\u20131126 (2009).","journal-title":"C. R. Chim."},{"key":"BFnrurol2013274_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4155\/fmc.12.210","volume":"5","author":"L Yin","year":"2013","unstructured":"Yin, L. & Hu, Q. Drug discovery for breast cancer and coinstantaneous cardiovascular disease: what is the future? Future Med. Chem. 5, 359\u2013362 (2013).","journal-title":"Future Med. Chem."},{"key":"BFnrurol2013274_CR40","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1021\/jm3003872","volume":"55","author":"L Yin","year":"2012","unstructured":"Yin, L.  et al. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome. J. Med. Chem. 55, 6629\u20136633 (2012).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR41","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1021\/jm400240r","volume":"56","author":"J Emmerich","year":"2013","unstructured":"Emmerich, J., Hu, Q., Hanke, N. & Hartmann, R. W. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type. J. Med. Chem. 56, 6022\u20136032 (2013).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR42","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1021\/jm301844q","volume":"56","author":"S Gobbi","year":"2013","unstructured":"Gobbi, S.  et al. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 1\u03b2-hydroxylase inhibition. J. Med. Chem. 56, 1723\u20131729 (2013).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR43","doi-asserted-by":"publisher","first-page":"e48048","DOI":"10.1371\/journal.pone.0048048","volume":"7","author":"L Yin","year":"2012","unstructured":"Yin, L., Hu, Q. & Hartmann, R. W. 3-Pyridinyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2. PLoS ONE 7, e48048 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrurol2013274_CR44","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1021\/jm3004637","volume":"55","author":"Q Hu","year":"2012","unstructured":"Hu, Q., Yin, L. & Hartmann, R. W. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer. J. Med. Chem. 55, 7080\u20137089 (2012).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/jm301408t","volume":"56","author":"L Yin","year":"2013","unstructured":"Yin, L., Hu, Q. & Hartmann, R. W. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase\/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks. J. Med. Chem. 56, 460\u2013470 (2013).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR46","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1021\/jm981017j","volume":"41","author":"M Jarman","year":"1998","unstructured":"Jarman, M., Barrie, S. E. & Llera, J. M. The 16,17-double bond is needed for irreversible inhibition of human cytochrome P45017\u03b1 by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3\u03b2-ol) and related steroidal inhibitors. J. Med. Chem. 41, 5375\u20135381 (1998).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR47","unstructured":"Janseen. Highlights of prescribing information: Zytiga\u00ae[online], (2013)."},{"key":"BFnrurol2013274_CR48","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"CJ Ryan","year":"2010","unstructured":"Ryan, C. J.  et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28, 1481\u20131488 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3109\/00498254.2012.721022","volume":"43","author":"M Acharya","year":"2013","unstructured":"Acharya, M.  et al. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica 43, 379\u2013389 (2013).","journal-title":"Xenobiotica"},{"key":"BFnrurol2013274_CR50","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O'Donnell","year":"2004","unstructured":"O'Donnell, A.  et al. Hormonal impact of the 17\u03b1-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90, 2317\u20132325 (2004).","journal-title":"Br. J. Cancer"},{"key":"BFnrurol2013274_CR51","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","volume":"7","author":"I Tannock","year":"1989","unstructured":"Tannock, I.  et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7, 590\u2013597 (1989).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR52","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard, G.  et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742\u20133748 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR53","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","volume":"17","author":"CJ Ryan","year":"2011","unstructured":"Ryan, C. J.  et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res. 17, 4854\u20134861 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2013274_CR54","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"DC Danila","year":"2010","unstructured":"Danila, D. C.  et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496\u20131501 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR55","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","volume":"28","author":"AH Reid","year":"2010","unstructured":"Reid, A. H.  et al. Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489\u20131495 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR56","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan, C. J.  et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138\u2013148 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2013274_CR57","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis, C. J.  et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13, 1210\u20131217 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrurol2013274_CR58","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/annonc\/mds585","volume":"24","author":"CN Sternberg","year":"2013","unstructured":"Sternberg, C. N.  et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann. Oncol. 24, 1017\u20131025 (2013).","journal-title":"Ann. Oncol."},{"key":"BFnrurol2013274_CR59","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","volume":"30","author":"E Efstathiou","year":"2012","unstructured":"Efstathiou, E.  et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30, 637\u2013643 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR60","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2013)."},{"key":"BFnrurol2013274_CR61","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S.  et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrurol2013274_CR62","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi, K.  et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983\u2013992 (2012).","journal-title":"Lancet Oncol."},{"key":"BFnrurol2013274_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2013)."},{"key":"BFnrurol2013274_CR64","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","volume":"22","author":"EJ Small","year":"2004","unstructured":"Small, E. J.  et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025\u20131033 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR65","unstructured":"Eisner, J. R.  et al. Assessment of steroid hormones upstream of P450c17 (CYP17) in chemically castrate male rhesus monkeys following treatment with the CYP17 inhibitors VT-464 and abiraterone acetate (AA) [abstract]. Endocr. Rev. 33 (03_MeetingAbstracts), SAT-266 (2012)."},{"key":"BFnrurol2013274_CR66","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/jm00013a022","volume":"38","author":"GA Potter","year":"1995","unstructured":"Potter, G. A., Barrie, S. E., Jarman, M. & Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P450 17\u03b1-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463\u20132471 (1995).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR67","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-12-0908","volume":"18","author":"R Li","year":"2012","unstructured":"Li, R.  et al. Abiraterone inhibits 3\u03b2-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin. Cancer Res. 18, 3571\u20133579 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2013274_CR68","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1074\/jbc.M111.261933","volume":"287","author":"HS Soifer","year":"2012","unstructured":"Soifer, H. S.  et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J. Biol. Chem. 287, 3777\u20133787 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrurol2013274_CR69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","volume":"129","author":"M Yamaoka","year":"2012","unstructured":"Yamaoka, M.  et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid Biochem. Mol. Biol. 129, 115\u2013128 (2012).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"BFnrurol2013274_CR70","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1016\/j.bmc.2011.08.066","volume":"19","author":"T Kaku","year":"2011","unstructured":"Kaku, T.  et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg. Med. Chem. 19, 6383\u20136399 (2011).","journal-title":"Bioorg. Med. Chem."},{"issue":"Suppl. 15","key":"BFnrurol2013274_CR71","doi-asserted-by":"publisher","first-page":"a3084","DOI":"10.1200\/jco.2010.28.15_suppl.3084","volume":"28","author":"R Dreicer","year":"2010","unstructured":"Dreicer, R.  et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I\/II, open-label study [abstract 3084]. J. Clin. Oncol. 28 (Suppl. 15), a3084 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 5","key":"BFnrurol2013274_CR72","doi-asserted-by":"publisher","first-page":"a98","DOI":"10.1200\/jco.2012.30.5_suppl.98","volume":"30","author":"DB Agus","year":"2012","unstructured":"Agus, D. B.  et al. Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I\/II study [abstract 98]. J. Clin. Oncol. 30 (Suppl. 5), a98 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 5","key":"BFnrurol2013274_CR73","doi-asserted-by":"publisher","first-page":"a4549","DOI":"10.1200\/jco.2012.30.15_suppl.4549","volume":"30","author":"DJ George","year":"2012","unstructured":"George, D. J.  et al. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): updated results of a phase II study [abstract 4549]. J. Clin. Oncol. 30 (Suppl. 5), a4549 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"BFnrurol2013274_CR74","doi-asserted-by":"publisher","first-page":"aTPS4693","DOI":"10.1200\/jco.2012.30.15_suppl.tps4693","volume":"30","author":"R Dreicer","year":"2012","unstructured":"Dreicer, R.  et al. A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy [abstract TPS4693]. J. Clin. Oncol. 30 (Suppl. 15), aTPS4693 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 5","key":"BFnrurol2013274_CR75","doi-asserted-by":"publisher","first-page":"a198","DOI":"10.1200\/jco.2012.30.5_suppl.198","volume":"30","author":"JR Eisner","year":"2012","unstructured":"Eisner, J. R.  et al. VT-464: a novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC) [abstract 198]. J. Clin. Oncol. 30 (Suppl. 5), a198 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR76","unstructured":"Abbott, D. H.  et al. Plasma steroid concentrations in male rhesus monkeys following treatment with the P450c17 (CYP17) inhibitors VT-464 and abiraterone acetate: a comparison to human 17,20-Lyase (lyase) and combined lyase\/17\u03b1-hydroxylase (hydroxylase) deficiencies [abstract]. Endocr. Rev. 33 (03_MeetingAbstracts), SAT-256 (2012)."},{"issue":"Suppl. 5","key":"BFnrurol2013274_CR77","doi-asserted-by":"publisher","first-page":"a64","DOI":"10.1200\/jco.2012.30.5_suppl.64","volume":"30","author":"ST Pisle","year":"2012","unstructured":"Pisle, S. T.  et al. Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model [abstract 64]. J. Clin. Oncol. 30 (Suppl. 5), a64 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR78","unstructured":"European Medicines Agency. ClinicalTrialsRegister.eu [online], (2013)."},{"key":"BFnrurol2013274_CR79","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel, E. A.  et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913\u20135925 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrurol2013274_CR80","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1021\/jm040202w","volume":"48","author":"VD Handratta","year":"2005","unstructured":"Handratta, V. D.  et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972\u20132984 (2005).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR81","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","volume":"7","author":"T Vasaitis","year":"2008","unstructured":"Vasaitis, T.  et al. Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitor VN\/124-1 in prostate cancer. Mol. Cancer Ther. 7, 2348\u20132357 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrurol2013274_CR82","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-08-0336","volume":"7","author":"R Bruno","year":"2008","unstructured":"Bruno, R., Gover, T., Burger, A., Brodie, A. M. H. & Njar, V. C. O. 17\u03b1-Hydroxylase\/17,20 lyase inhibitor VN\/124\u20131 inhibits growth of androgen independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol. Cancer Ther. 7, 2828\u20132836 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrurol2013274_CR83","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.steroids.2011.06.002","volume":"76","author":"RD Bruno","year":"2011","unstructured":"Bruno, R. D.  et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN\/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN\/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids 76, 1268\u20131279 (2011).","journal-title":"Steroids"},{"key":"BFnrurol2013274_CR84","unstructured":"American Association for Cancer Research. Early clinical data show galeterone safe, effective against prostate cancer [online], (2012)."},{"key":"BFnrurol2013274_CR85","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2013)."},{"key":"BFnrurol2013274_CR86","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2217\/fon.09.117","volume":"5","author":"SS Dutt","year":"2009","unstructured":"Dutt, S. S. & Gao, A. C. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 5, 1403\u20131413 (2009).","journal-title":"Future Oncol."},{"key":"BFnrurol2013274_CR87","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1021\/jm100317b","volume":"53","author":"Q Hu","year":"2010","unstructured":"Hu, Q., Jagusch, C., Hille, U. E., Haupenthal, J. & Hartmann, R. W. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17\/CYP11B1 inhibitors for the treatment of prostate cancer. J. Med. Chem. 53, 5749\u20135758 (2010).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR88","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1021\/jm400484p","volume":"56","author":"MA Pinto-Bazurco Mendieta","year":"2013","unstructured":"Pinto-Bazurco Mendieta, M. A., Hu, Q., Engel, M. & Hartmann, R. W. Highly potent and selective non-steroidal dual inhibitors of CYP17\/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases. J. Med. Chem. 56, 6101\u20136107 (2013).","journal-title":"J. Med. Chem."},{"key":"BFnrurol2013274_CR89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","volume":"27","author":"JA Efstathiou","year":"2008","unstructured":"Efstathiou, J. A.  et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol. 27, 92\u201399 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrurol2013274_CR90","unstructured":"US National Library of Medicine. ClinicalTrials.gov [online], (2013)."},{"key":"BFnrurol2013274_CR91","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/B978-0-12-396521-9.00011-5","volume-title":"Cancer Drug Design and Discovery","author":"Q Hu","year":"2014","unstructured":"Hu, Q. & Hartmann, R. W. in Cancer Drug Design and Discovery (ed. Neidle, S.) 319\u2013356 (Academic Press, 2014)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2013.274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2013.274","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2013.274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T18:06:13Z","timestamp":1650045973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2013.274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,26]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["BFnrurol2013274"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2013.274","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,26]]},"assertion":[{"value":"26 November 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}